La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Vertex Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 6/6
Vertex Pharmaceuticals possède un total de capitaux propres de $14.8B et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $20.1B et de $5.4B. L'EBIT de Vertex Pharmaceuticals est $4.2B ce qui fait que son ratio de couverture des intérêts -6.5. Elle dispose de liquidités et de placements à court terme de $5.8B.
Informations clés
0%
Ratio d'endettement
US$0
Dette
| Ratio de couverture des intérêts | -6.5x |
| Argent liquide | US$5.80b |
| Fonds propres | US$14.77b |
| Total du passif | US$5.36b |
| Total des actifs | US$20.13b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03Analyse de la situation financière
Passif à court terme: Les actifs à court terme de VRTX ( $8.9B ) dépassent ses passifs à court terme ( $3.5B ).
Passif à long terme: Les actifs à court terme de VRTX ( $8.9B ) dépassent ses passifs à long terme ( $1.8B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: VRTX est sans dette.
Réduire la dette: VRTX n'avait aucune dette il y a 5 ans.
Couverture de la dette: VRTX n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.
Couverture des intérêts: VRTX n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.